Insight Molecular Diagnostics Inc. (IMDX)
Official siteHEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ
Market Cap: $70.03M
Last updated: Nov 17, 2026 at 11:06 AM ET
Insight Molecular Diagnostics Inc. (IMDX) Earnings: Report Dates and Results
Insight Molecular Diagnostics (IMDX) is expected to report earnings on Mar 24, 2027. In the quarter ended Jun 30, 2026, Insight Molecular Diagnostics reported EPS of -$0.23, in line with the -$0.23 estimate. It beat the EPS estimate in 3 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
IMDX has an expected report date of Mar 24, 2027.
IMDX Earnings Call
The latest IMDX earnings call transcript on file is labeled 2026Q2.
Read the 2026Q2 transcriptEarnings History
Of the 38 quarters below that had an estimate, IMDX beat 11, missed 23 and matched 4. Revenue for the quarter ended Jun 30, 2026 was $239000, down 53.9% from $518000 a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun 30, 2026 | -$0.23 | -$0.23 | -$0.23 - -$0.23 | 0.00% | In line | N/A | 1 | 0 up, 0 down | Aug 10, 2026 | $239000 |
| Mar 31, 2026 | -$0.12 | -$0.26 | -$0.31 - -$0.24 | +53.85% | Beat | N/A | 4 | 0 up, 2 down | May 13, 2026 | $32000 |
| Dec 31, 2025 | -$0.72 | -$0.24 | -$0.24 - -$0.24 | -203.16% | Miss | N/A | 1 | 0 up, 0 down | Mar 26, 2026 | $1.14M |
| Sep 30, 2025 | -$0.23 | -$0.24 | N/A | +4.17% | Beat | N/A | 1 | 0 up, 0 down | Nov 10, 2025 | $260000 |
| Jun 30, 2025 | -$0.30 | -$0.24 | -$0.24 - -$0.24 | -25.00% | Miss | N/A | 1 | 0 up, 0 down | Aug 11, 2025 | $518000 |
| Mar 31, 2025 | -$0.23 | -$0.25 | N/A | +8.00% | Beat | N/A | N/A | N/A | May 12, 2025 | $2.14M |
| Dec 31, 2024 | -$1.93 | -$1.12 | N/A | -72.32% | Miss | N/A | N/A | N/A | Mar 24, 2025 | $1.49M |
| Sep 30, 2024 | -$0.98 | -$0.44 | N/A | -122.73% | Miss | N/A | N/A | N/A | Nov 12, 2024 | $115000 |
| Jun 30, 2024 | -$0.43 | -$0.37 | N/A | -16.22% | Miss | N/A | N/A | N/A | Aug 8, 2024 | $104000 |
| Mar 31, 2024 | -$2.07 | -$0.99 | N/A | -109.09% | Miss | -5275.0% | N/A | N/A | Apr 12, 2024 | $176000 |
| Sep 30, 2023 | -$0.62 | -$0.78 | N/A | +20.51% | Beat | N/A | N/A | N/A | Nov 9, 2023 | $429000 |
| Jun 30, 2023 | -$0.73 | -$0.59 | N/A | -23.73% | Miss | N/A | N/A | N/A | Aug 10, 2023 | $463000 |
| Mar 31, 2023 | $0.04 | -$0.08 | N/A | +150.00% | Beat | N/A | N/A | N/A | May 11, 2023 | $297000 |
| Dec 31, 2022 | -$2.25 | -$1.60 | N/A | -40.63% | Miss | N/A | N/A | N/A | Mar 29, 2023 | $274000 |
| Sep 30, 2022 | -$2.43 | -$2.33 | N/A | -4.29% | Miss | N/A | N/A | N/A | Nov 10, 2022 | $67000 |
| Jun 30, 2022 | -$2.57 | -$2.00 | N/A | -28.50% | Miss | N/A | N/A | N/A | Aug 10, 2022 | $237000 |
| Mar 31, 2022 | -$3.24 | -$2.00 | N/A | -62.00% | Miss | N/A | N/A | N/A | May 11, 2022 | $380000 |
| Dec 31, 2021 | -$0.39 | -$0.12 | N/A | -217.33% | Miss | N/A | N/A | N/A | Mar 10, 2022 | N/A |
| Sep 30, 2021 | -$2.76 | -$2.00 | N/A | -38.00% | Miss | N/A | N/A | N/A | Nov 9, 2021 | $984000 |
| Jun 30, 2021 | -$2.58 | -$1.84 | N/A | -40.22% | Miss | N/A | N/A | N/A | Aug 10, 2021 | $2.03M |
| Mar 31, 2021 | -$1.00 | -$1.88 | N/A | +46.81% | Beat | N/A | N/A | N/A | May 17, 2021 | $1.12M |
| Dec 31, 2020 | -$0.09 | -$0.11 | N/A | +16.28% | Beat | N/A | N/A | N/A | Mar 16, 2021 | $502000 |
| Sep 30, 2020 | -$2.53 | -$1.84 | N/A | -37.50% | Miss | N/A | N/A | N/A | Nov 12, 2020 | $555000 |
| Jun 30, 2020 | -$2.64 | -$2.05 | N/A | -28.78% | Miss | N/A | N/A | N/A | Jul 29, 2020 | $143000 |
| Mar 31, 2020 | -$2.50 | -$2.12 | N/A | -17.92% | Miss | N/A | N/A | N/A | May 12, 2020 | $16000 |
| Dec 31, 2019 | -$0.15 | -$0.09 | N/A | -66.67% | Miss | N/A | N/A | N/A | Mar 25, 2020 | N/A |
| Sep 30, 2019 | -$1.98 | -$1.64 | N/A | -20.73% | Miss | N/A | N/A | N/A | Nov 14, 2019 | N/A |
| Jun 30, 2019 | -$1.94 | -$1.72 | N/A | -12.79% | Miss | N/A | N/A | N/A | Aug 14, 2019 | N/A |
| Mar 31, 2019 | -$1.58 | -$1.72 | N/A | +8.14% | Beat | N/A | N/A | N/A | Apr 1, 2019 | N/A |
| Sep 30, 2018 | -$1.60 | -$1.73 | N/A | +7.51% | Beat | N/A | N/A | N/A | Nov 13, 2018 | N/A |
| Jun 30, 2018 | -$1.89 | -$1.87 | N/A | -1.07% | Miss | N/A | N/A | N/A | Aug 14, 2018 | N/A |
| Mar 31, 2018 | -$2.51 | -$2.40 | N/A | -4.58% | Miss | N/A | N/A | N/A | Apr 2, 2018 | N/A |
| Sep 30, 2017 | -$2.53 | -$2.53 | N/A | 0.00% | In line | N/A | N/A | N/A | Nov 14, 2017 | N/A |
| Jun 30, 2017 | -$2.60 | -$2.33 | N/A | -11.59% | Miss | N/A | N/A | N/A | Aug 14, 2017 | N/A |
| Mar 31, 2017 | -$3.25 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Apr 28, 2017 | N/A |
| Dec 31, 2016 | -$2.00 | -$2.00 | N/A | 0.00% | In line | N/A | N/A | N/A | Feb 27, 2017 | N/A |
| Sep 30, 2016 | -$2.00 | -$2.00 | N/A | 0.00% | In line | N/A | N/A | N/A | Nov 10, 2016 | N/A |
| Jun 30, 2016 | -$2.00 | -$2.13 | N/A | +6.10% | Beat | N/A | N/A | N/A | Aug 11, 2016 | N/A |
| Mar 31, 2016 | -$2.40 | -$2.60 | N/A | +7.69% | Beat | N/A | N/A | N/A | May 16, 2016 | N/A |
| Dec 31, 2015 | -$2.88 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 30, 2016 | N/A |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$1.48, after -$6.72 the year before. It was -$2.88 for the year ended Dec 31, 2015, the oldest of the 8 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$1.48 | N/A |
| Dec 31, 2024 | -$6.72 | N/A |
| Dec 31, 2022 | -$10.49 | N/A |
| Dec 31, 2021 | -$6.73 | N/A |
| Dec 31, 2020 | -$7.76 | N/A |
| Dec 31, 2019 | -$20.03 | N/A |
| Dec 31, 2016 | -$8.40 | N/A |
| Dec 31, 2015 | -$2.88 | N/A |
Earnings Calls
The 6 most recent earnings calls are listed below; the latest, 2026Q2 for the period ended Jun 30, 2026, runs about 3,900 words across 8 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q2 | Jun 30, 2026 | 3,856 | 8 | |
| 2026Q1 | Mar 31, 2026 | 3,259 | 7 | |
| 2025Q4 | Dec 31, 2025 | 4,805 | 7 | |
| 2025Q3 | Sep 30, 2025 | 7,519 | 8 | |
| 2025Q2 | Jun 30, 2025 | 6,062 | 9 | |
| 2025Q1 | Mar 31, 2025 | 5,019 | 9 |
2026Q2 Earnings Call
Opening remarks
Gabrielle Woody Investor Relations / Moderator Welcome, everyone, and thank you for joining us to discuss Insight Molecular Diagnostics' second quarter 2026 results. If you have not seen today's shareholder letter, please visit Insight Molecular Diagnostics' Investor Relations page at investors.imdxinc.com. Today's prepared remarks build upon the information already shared in this robust letter. Joining us today are Insight Molecular Diagnostics' President and CEO, Josh Riggs; Chief Science Officer, Ekke Schutz; and CFO, Andrea James. We also have our analysts with us as panelists. After our prepared remarks, our analysts may ask questions. Before turning the call over to Josh Riggs, I'd like to review our safe harbor. The company will make projections and forward-looking statements regarding future events. Any statements that are not historical facts are forward-looking statements. These statements are made pursuant to and within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We encourage you to review the company's SEC filings, including the company's most recent Form 10-K and subsequent Form 10-Q, which identify risks and uncertainties that may cause future actual results or events to differ materially. Please note the forward-looking statements made during today's call speak only to the date they are made, and Insight Molecular Diagnostics undertakes no obligation to update them. And with that, I would like to now turn the call over to Josh Riggs.
Joshua Riggs President and CEO Thanks, Gabby. It feels great to be coming to you today with line of sight on expected FDA marketing authorization for GraftAssureDx. We have 3 brief but promising takeaways today in our shareholder letter. The first is that after 3 years of rigorous kitted product development, we believe that we are seeing the light at the end of the tunnel on having a regulated product. Back in July, we got our additional information letter from the FDA. It's a normal part of the Class II process where they ask for some additional data and clarification on intended use as part of their review. Since submitting back in March, we've about tripled the amount of samples collected in the study and feel good about addressing all their questions and comments. Prior to submitting our next data package, we are going to have an SIR meeting with the FDA. This meeting is a lot like the Q-Sub process where you get direct and written feedback on your planned approach. It's an opportunity for both parties to make sure there is clear understanding on what is needed to get through to authorization and clear up any potential misunderstandings. Once we have the green light from them, the next steps are pretty straightforward. We package it all up, hit submit and wait for their response.
Frequently Asked Questions About IMDX
When is Insight Molecular Diagnostics's next earnings date?
Insight Molecular Diagnostics's next earnings report is expected for Mar 24, 2027.
Did IMDX beat earnings estimates last quarter?
Insight Molecular Diagnostics reported EPS of -$0.23 for the quarter ended Jun 30, 2026, in line with the -$0.23 estimate.
What EPS do analysts expect from IMDX next quarter?
The consensus EPS estimate for Insight Molecular Diagnostics for the quarter ending Dec 31, 2026 is -$0.24 from 7 analysts, with estimates from -$0.24 to -$0.23.
How often does IMDX beat earnings estimates?
Insight Molecular Diagnostics beat the EPS estimate in 3 of the last 8 quarters, with an average surprise of -44.65%.
IMDX pages: Overview, Earnings, Forecast, Financials, Competitors